PET/CT beats CT and bone scans for detecting metastatic prostate cancer: study

Researchers have found that a PET/CT scan is more sensitive for detecting metastatic prostate cancer than the imaging modalities currently in use, which could hold the key for providing more timely treatment.

In the study, published in the January issue of the Journal of Nuclear Medicine, the researchers compared a PET/CT scan using the radiotracer F-18 DCFBC to conventional imaging modalities — an expanded Tc-99m-methylene diphosphonate (MDP) bone scan and contrast-enhanced CT of the chest, abdomen and pelvis — to detect prostate-specific membrane antigen (PSMA), which is associated with prostate cancer metastases. Read more.